Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

医学 结直肠癌 肿瘤科 内科学 转移 直肠 临床终点 癌症 临床试验
作者
Jan Franko,Qian Shi,Jeffrey P. Meyers,Tim Maughan,Richard Adams,Michel Seymour,Leonard B. Saltz,Cornelis J.A. Punt,Miriam Koopman,Christophe Tournigand,Niall Christopher Tebbutt,Eduardo Díaz‐Rubio,John Souglakos,Alfredo Falcone,Benoist Chibaudel,Volker Heinemann,Joseph Moen,Aimery de Gramont,Daniel J. Sargent,Axel F. Grothey
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:17 (12): 1709-1719 被引量:743
标识
DOI:10.1016/s1470-2045(16)30500-9
摘要

Background Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. Methods We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008. Trials were included if protocols explicitly pre-specified and solicited for patients with peritoneal involvement in the trial data collection process or had done a formal peritoneum-focused review of individual pre-treatment scans. We used stratified multivariable Cox models to assess the prognostic associations of peritoneal metastatic colorectal cancer with overall survival and progression-free survival, adjusting for other key clinical-pathological factors (age, sex, Eastern Cooperative Oncology Group (ECOG) performance score, primary tumour location [colon vs rectum], previous treatment, and baseline BMI). The primary endpoint was difference in overall survival between populations with and without peritoneal metastases. Findings Individual patient data were available for 10 553 patients. 9178 (87%) of 10 553 patients had non-peritoneal metastatic colorectal cancer (4385 with one site of metastasis, 4793 with two or more sites of metastasis), 194 (2%) patients had isolated peritoneal metastatic colorectal cancer, and 1181 (11%) had peritoneal metastatic colorectal cancer and other organ involvement. These groups were similar in age, ethnic origin, and use of targeted treatment. Patients with peritoneal metastatic colorectal cancer were more likely than those with non-peritoneal metastatic colorectal cancer to be women (565 [41%] of 1371 vs 3312 [36%] of 9169 patients; p=0·0003), have colon primary tumours (1116 [84%] of 1334 patients vs 5603 [66%]; p<0·0001), and have performance status of 2 (136 [10%] vs 521 [6%]; p<0·0001). We recorded a higher proportion of patients with mutated BRAF in patients with peritoneal-only (eight [18%] of 44 patients with available data) and peritoneal metastatic colorectal cancer with other sites of metastasis (34 [12%] of 289), compared with patients with non-peritoneal metastatic colorectal cancer (194 [9%] of 2230; p=0·028 comparing the three groups). Overall survival (adjusted HR 0·75, 95% CI 0·63–0·91; p=0·003) was better in patients with isolated non-peritoneal sites than in those with isolated peritoneal metastatic colorectal cancer. Overall survival of patients with two of more non-peritoneal sites of metastasis (adjusted HR 1·04, 95% CI 0·86–1·25, p=0.69) and those with peritoneal metastatic colorectal cancer plus one other site of metastasis (adjusted HR 1·10, 95% CI 0·89–1·37, p=0·37) was similar to those with isolated peritoneal metastases. Compared with patients with isolated peritoneal metastases, those with peritoneal metastases and two or more additional sites of metastasis had the shortest survival (adjusted HR 1·40; CI 1·14–1·71; p=0·0011). Interpretation Patients with peritoneal metastatic colorectal cancer have significantly shorter overall survival than those with other isolated sites of metastases. In patients with several sites of metastasis, poor survival is a function of both increased number of metastatic sites and peritoneal involvement. The pattern of metastasis and in particular, peritoneal involvement, results in prognostic heterogeneity of metastatic colorectal cancer. Funding None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ss的应助被YYY采纳,获得10
1秒前
领导范儿的应助被月蚀六花采纳,获得10
2秒前
细心无声完成签到,获得积分10
2秒前
4秒前
细心无声发布了新的文献求助10
4秒前
hcx完成签到,获得积分10
4秒前
5秒前
acadedog完成签到,获得积分10
5秒前
deardorff发布了新的文献求助20
6秒前
6秒前
星辰大海的应助被谨慎的秋烟采纳,获得30
7秒前
8秒前
佳loong完成签到,获得积分10
9秒前
LuoYR@SZU完成签到,获得积分10
9秒前
9秒前
费劲来到这的Rua完成签到,获得积分10
9秒前
小未来完成签到,获得积分10
10秒前
10秒前
小林子完成签到 ,获得积分10
11秒前
11秒前
七七完成签到,获得积分10
12秒前
jsdiohfsiodhg完成签到,获得积分10
12秒前
chenmianyuan完成签到 ,获得积分10
13秒前
14秒前
15秒前
tian完成签到,获得积分10
15秒前
cosine发布了新的文献求助10
16秒前
喜悦的绫完成签到 ,获得积分10
16秒前
17秒前
18秒前
科研小虫完成签到,获得积分10
19秒前
Lewis完成签到 ,获得积分10
19秒前
小蘑菇的应助被科研通管家采纳,获得10
20秒前
wanci的应助被科研通管家采纳,获得10
20秒前
CipherSage的应助被科研通管家采纳,获得10
20秒前
Akim的应助被科研通管家采纳,获得30
20秒前
guamo完成签到,获得积分10
20秒前
20秒前
kiluto完成签到,获得积分10
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621